Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Engineered human gamma delta T cells for multiple myeloma immunotherapy
FY 2019-20
Summary
"Adoptive cell therapy using engineered human T cells can, in many cases, produce a complete response in patients with refractory relapsed hematological malignancies who otherwise lack treatment options. However, the current cost of the commercially available engineered T cell therapies begins at the expensive price of $500,000 CAD, and is consequently not financially sustainable within the Canadian healthcare system. A major cost driver is the inefficient manufacturing process whereby each patient's treatment is individually manufactured from their own T cells, a necessity for the type of T cells currently used in commercial engineered T cell therapies. These therapies are currently manufactured in a T cell subset known as alphaβ T cells, which cause graft versus host disease when delivered to unrelated patients. A separate subset of T cells, γδ T cells, do not cause graft versus host disease and therefore represent a potential off-the-shelf solution that can be mass produced to reduce manufacturing costs. My project will focus on developing chimeric receptor engineered human γδ T cells for Multiple Myeloma as a promising new therapy for the currently incurable hematological malignancy. Our group has designed chimeric receptors that redirect human alphaβ T cells to kill Multiple Myeloma cells through targeting of B Cell Maturation Antigen. I will adapt our existing chimeric receptors for human γδ T cells by augmenting the chimeric receptor intracellular signalling domains to optimize γδ T cell activation and multiple myeloma-specific killing. My ultimate goal is to produce an off-the-shelf engineered human γδ T cell for cancer therapy that will reduce the cost of these expensive therapies and increase the number of patients who can access these exciting treatments. "
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
428678
Name
Asbury Sarah
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Engineered human gamma delta T cells for multiple myeloma immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adaptive Immune System; Allogeneic; Chimeric Antigen Receptor (Car) T Cells; Engineered Adoptive T Cell Therapy; Gamma Delta T Cells; Genetic Engineering; Immunology; Immunotherapy; Multiple Myeloma; Scalable Manufacturing
Abstract
"Adoptive cell therapy using engineered human T cells can, in many cases, produce a complete response in patients with refractory relapsed hematological malignancies who otherwise lack treatment options. However, the current cost of the commercially available engineered T cell therapies begins at the expensive price of $500,000 CAD, and is consequently not financially sustainable within the Canadian healthcare system. A major cost driver is the inefficient manufacturing process whereby each patient's treatment is individually manufactured from their own T cells, a necessity for the type of T cells currently used in commercial engineered T cell therapies. These therapies are currently manufactured in a T cell subset known as alphaβ T cells, which cause graft versus host disease when delivered to unrelated patients. A separate subset of T cells, γδ T cells, do not cause graft versus host disease and therefore represent a potential off-the-shelf solution that can be mass produced to reduce manufacturing costs. My project will focus on developing chimeric receptor engineered human γδ T cells for Multiple Myeloma as a promising new therapy for the currently incurable hematological malignancy. Our group has designed chimeric receptors that redirect human alphaβ T cells to kill Multiple Myeloma cells through targeting of B Cell Maturation Antigen. I will adapt our existing chimeric receptors for human γδ T cells by augmenting the chimeric receptor intracellular signalling domains to optimize γδ T cell activation and multiple myeloma-specific killing. My ultimate goal is to produce an off-the-shelf engineered human γδ T cell for cancer therapy that will reduce the cost of these expensive therapies and increase the number of patients who can access these exciting treatments. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Asbury, Sarah
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~